S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.

S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.

Bibliographic Details
Main Authors:	Matthew J. Frank, John Baird, Anne Kramer, Shabnum Patel, Bita Sahaf, Juliana Craig, Emma Crawford, Sheren Younes, Jean Oak, Yasodha Natkunan, Jay Spiegel, Zachary Ehlinger, Harshini Chinnasamy, Warren Reynolds, Hrishi Srinagesh, Yi-Jiun Su, Emily Egeler, Steven Feldman, Crystal Mackall, Lori Muffly, David Miklos
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967832.33621.69

Similar Items

Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
by: Crystal Mackall, et al.
Published: (2020-10-01)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
by: Leonardo M. R. Ferreira, et al.
Published: (2021-11-01)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
by: Lihe Su, et al.
Published: (2022-12-01)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
by: Wenjie Li, et al.
Published: (2023-03-01)

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy
by: Nirali N. Shah, et al.
Published: (2019-08-01)

Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant
by: George Chen, et al.
Published: (2022-10-01)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
by: Yun Liang, et al.
Published: (2021-02-01)

Transcriptional rewiring in CD8+ T cells: implications for CAR-T cell therapy against solid tumours
by: Shamini Srinivasan, et al.
Published: (2024-09-01)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
by: Yinqiang Zhang, et al.
Published: (2023-04-01)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
by: Nathan J. Fergusson, et al.
Published: (2023-04-01)

CAR T cell therapy
by: Naoki Hosen
Published: (2021-04-01)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
by: Lihong An, et al.
Published: (2022-04-01)

CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?
by: Carlos Rangel-Peláez, et al.
Published: (2024-12-01)

Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies
by: Marika Guercio, et al.
Published: (2021-10-01)

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
by: Mazyar Shadman, et al.
Published: (2019-10-01)

CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
by: Tingdang Liu, et al.
Published: (2023-10-01)

Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies
by: Harjeet Singh, et al.
Published: (2022-11-01)

CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy
by: Miriam Y. Kim, et al.
Published: (2021-08-01)

279 Preclinical evaluation of allogeneic CD19 CAR T cells expressing an anti-rejection CD70 CAR
by: Kristen Zhang, et al.
Published: (2023-11-01)

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
by: Ugo Testa, et al.
Published: (2024-02-01)

Donor T cells for CAR T cell therapy
by: Tiffany C. Y. Tang, et al.
Published: (2022-04-01)

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
by: Crystal Mackall, et al.
Published: (2020-10-01)

Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology
by: Konstantinos Lontos, et al.
Published: (2022-12-01)

CAR-T CELL THERAPY IN CLL
by: Selver Kurt
Published: (2024-12-01)

CAR T Cell Therapy for Neuroblastoma
by: Rebecca M. Richards, et al.
Published: (2018-10-01)

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
by: Vinodh Pillai, et al.
Published: (2019-11-01)

Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study
by: Maren Claus, et al.
Published: (2024-12-01)

Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
by: Inna Y. Gong, et al.
Published: (2024-08-01)

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
by: Na Zheng, et al.
Published: (2024-01-01)

P1376: IDENTIFICATION OF SURFACEOME CHANGES IN CD19 CAR-T THERAPY-RESISTANT LYMPHOMA CELLS
by: Marta Krawczyk, et al.
Published: (2023-08-01)

322 Preclinical assessment of allogeneic Anti-CD5 γδ CAR-T therapy for T-Cell malignancies
by: Young Ho Lee, et al.
Published: (2023-11-01)

Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
by: Limin Xing, et al.
Published: (2021-12-01)

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
by: Paolo F. Caimi, et al.
Published: (2021-10-01)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
by: Yao Sun, et al.
Published: (2021-10-01)

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
by: Yi Zhang, et al.
Published: (2020-10-01)

High Prevalence of PNH-phenotype Cells in Patients Who Received CD19-targeted CAR T-cell Therapy
by: Kyoko Yoshihara, et al.
Published: (2021-09-01)

CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
by: Andrea Timpanaro, et al.
Published: (2023-11-01)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
by: Lefu Huang, et al.
Published: (2022-12-01)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
by: Hanren Dai, et al.
Published: (2020-04-01)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
by: Simone Thomas, et al.
Published: (2023-01-01)